AI-powered decision support to boost thrombolysis for ischemic stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized, open-label trial with blinded endpoints comparing an AI-assisted thrombolysis decision tool added to routine care versus standard guidelines. Cluster randomization occurs at the level of attending physicians. The study measures whether the AI tool increases the proportion of patients treated with intravenous thrombolysis within 24 hours of onset and examines effects on clinical outcomes, treatment timelines, and safety. Eligible adults with acute ischemic stroke within 24 hours, confirmed imaging, and consent are enrolled at Liuyang Jili Hospital under Capital Medical University guidance. The trial does not alter standard care except for the AI tool guidance, and no delays to care are permitted for research purposes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years.
2. Clinical diagnosis of acute ischemic stroke.
3. Onset time (last known well) \<24 hours.
4. CT or MRI examination excluding intracerebral hemorrhage.
5. Signed informed consent by the patient or a legally authorized representative

Exclusion Criteria:

1. Currently participating in another interventional clinical trial related to drugs or devices.
2. Pregnant women.
3. Has received intravenous thrombolysis at another hospital.
4. Has completed a definitive reperfusion therapy decision at another hospital and is transferred to this hospital solely for follow-up observation or rehabilitation.

Where it's running

• Liuyang Jili Hospital
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Xunming Ji
• Email: jixm@ccmu.edu.cn
• Phone: 01083198962

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tegoprazan to prevent GI complications in ischemic stroke patients on antiplatelet therapy

  This trial tests whether tegoprazan can lower gastrointestinal complications in adults with ischemic stroke or TIA who are starting antiplatelet therapy.

  Recruiting at 24 sites Phase 3 Hanyang University · Busan, Busan and 23 other locations · NCT07687706

• Intra-arterial Thrombolysis for Acute Ischemic Stroke with Medium Vessel Occlusion

  This trial tests whether delivering a clot-busting medicine directly into the brain’s medium vessels helps improve outcomes for adults with acute ischemic stroke caused by MeVO, on top of standard care.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07668323

• Single Bolus Non-immunogenic Staphylokinase in Acute Ischemic Stroke (4.5–24 hours)

  This trial tests a single 10 mg bolus of non-immunogenic staphylokinase versus placebo in adults with acute ischemic stroke 4.5–24 hours after onset to see if it helps restore blood flow and improve outcomes.

  Recruiting at 10 sites Phase 3 Supergene, LLC · Ryazan, Ryazan Oblast and 16 other locations · NCT07324837

• Imaging to detect impaired microcirculatory reperfusion after clot removal

  This project tests whether CT perfusion scans done after clot removal can spot poor tiny-vessel blood flow in adults with large-vessel ischemic stroke.

  Recruiting University of Cincinnati · Cincinnati, Ohio · NCT07099599

• Cerebrolysin for early rehabilitation after acute ischemic stroke

  This trial tests whether adding Cerebrolysin to standard early rehabilitation helps people with moderate acute ischemic stroke recover arm and overall function faster.

  Recruiting University Medical Centre Ljubljana · Ljubljana · NCT07043686

• Comparing two imaging techniques for detecting arterial obstructions in stroke patients

  This study is testing whether a new imaging method called TCCD is better than CT angiography for finding blocked arteries in stroke patients, especially in the Egyptian population.

  Recruiting Sohag University · Sohag · NCT06920303

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.